Phase I Study of Concurrent Selective Lymph Node Late Course Accelerated Hyper-fractionated Radiotherapy and Pemetrexed, Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma
Inclusion Criteria:
1. Signed informed consent; 2.Acquired pathological diagnosis; 3.Life expectancy≥6
months; 4.Age:18-75 years, male or female; 5.General state of health: ECOG 0-1 grade;
6.Without any chemotherapy or radiotherapy; 7.Subjects meet the following criteria
for the clinical laboratory:HG≥100g/L, WBC≥3.5X109 /L, neutrophilic
leukocyte≥1.5X109,PLT100X109 /L。CR≤1.5 x N,TB≤2.5XN,AST and ALT≤2.5xN,AKP≤2.5XN.
Exclusion Criteria:
- 1.Serious infection; 2.Uncontrollable diabetes; 3.Other serious diseases, such as
myocardial infarction in 6 months; 4. Participated other clinical trials in 4 weeks
or at present